News Releases

Keyword Search

Nov-15-2021
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
Nov-09-2021
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
Nov-04-2021
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
Nov-03-2021
Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies
Nov-02-2021
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
Nov-01-2021
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oct-29-2021
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results
Oct-05-2021
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets
Oct-01-2021
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Sep-20-2021
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies